There's a new brain cancer treatment in town and it might just mean a better and longer life for brain cancer patients.

 

Researchers from the University of California, San Francisco presented results at the American Association of Neurological Surgeons meeting in Miami this week regarding their study of a new brain cancer vaccine that has proven successful in phase two clinical trails.

 

The new vaccine is tailored to individual patients who suffer from recurrent glioblastoma multiforme, a type of cancer that kills thousands of Americans each year. The researchers evaluated patients from a number of facilities, including UCSF’s Helen Diller Family Comprehensive Cancer Center, the Seidman Cancer Center at University Hospitals Case Medical Center, and at New York-Presbyterian Hospital/Columbia University Medical Center, and compared treatment with the new vaccine with a standard treatment that lasted 47 weeks. 

 

They found that the vaccine treatment increased patients lives by several months compared to patients who underwent standard treatment.